• Preclinical development
  • AML
  • MDS
  • CMML
  • Targeted therapy
  • Immunotherapy
  • Alternative therapy
  • Chemotherapy
  • Preclinical research (TRL 4-5)

Study of the characterization of cell death for the evaluation of the efficacy of therapeutic solutions in the treatment of myeloid leukemias.

Demonstration of direct anti-tumor action or overcome resistance to conventional treatment.

Description

Scope of research activities

Preclinical research to demonstrate the efficacy of drug candidates in inducing leukemia cell death.

  • Demonstration of efficacy

Conduct of studies

Steps:

  • Study strategy analysis
  • Study design
  • Drafting of study plans
  • Organization, implementation and conduct of studies
  • Analysis and communication of results

Research infrastructure

Experimental and analysis platforms:

  • Apoptosis
  • Autophagy
  • Ferroptosis
  • BH3 profiling

Models:

  • Cell models (cell lines), primary cells (blood bone marrow), mouse models

Technical personnel:

  • 1 engineer 

Specifications

The platform

Analysis of the efficacy of drug candidates on the induction (direct or indirect) of cell death in leukemia models.

The studies

Demonstration of cell death induction:

  • Apoptosis: BH3 profiling, Caspase assay, SiRNA, AV/Dapi, loss of mitochondrial potential
  • Autophagy: LC3 conversion, Cathepsin assay, MET
  • Ferroptosis: Lipid peroxidation, reversion by specific inhibitors, GPX4 activity assay, evaluation of intracellular ROS.

Terms

OPALE entity

C3M (UMR-1065)

C3M (UMR-1065)
Guillaume Robert
Dr. Guillaume Robert
Team leader

Contact

Sandrine Palcy Dr. Sandrine Palcy
Business Development Director

Other offers

Contact us